Molecular point-of-care testing for influenza A/B and respiratory syncytial virus: comparison of workflow parameters for the ID Now and cobas Liat systems

Young, Stephen; Phillips, Jamie E.; Griego-Fullbright, Christen; Wagner, Aaron; Jim, Patricia; Chaudhuri, Sheena; Tang, Shaowu; Sickler, Joanna

doi:10.1136/jclinpath-2019-206242

Cited by 16 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For both assays, a NPS is required as the patient sample. The cobas Liat PCR System performs RT-PCR in 20 min, and displays amplification curves and cycle thresholds (C T ) [ 107 , 108 ]. This system allows for a small footprint and easy transfer to any laboratory or POC setting, and the assays provide minimal labor with a walk-away workflow.…”

Section: Clia-waived Nucleic Acid Diagnosticsmentioning

confidence: 99%

“…The instrument is USD 25,000, and each assay is around USD 72 per test. Overall, for the Influenza A/B Assay, this system provides a sensitivity of 100% and 94.4% to IAV and IBV, respectively, and a specificity of 98.3% and 100% to Influenza A and B, respectively [ 107 ]. For the Influenza A/B & RSV Assay, the system provides a sensitivity of 99.6% and 99.3% to IAV and IBV, respectively, and a specificity of 97.5% and 9.7% to IAV and IBV, respectively [ 108 ].…”

Section: Clia-waived Nucleic Acid Diagnosticsmentioning

confidence: 99%

“…This system performs an isothermal nucleic acid amplification test (NAAT) via a nicking enzyme and requires a NPS, direct nasal swab (NS), or both NPS and NS in viral transport medium (VTM) as the patient sample [ 108 ]. There are several advantages to this platform, including performance time, where positive results are displayed in 5 min, room temperature reagent storage, and small instrument size [ 107 ]. However, compared to other CLIA-waived influenza nucleic acid tests, there are several more workflow steps [ 109 ].…”

Section: Clia-waived Nucleic Acid Diagnosticsmentioning

confidence: 99%

“…There are several comparison studies of cobas Liat ID NOW, and Xpert Xpress platforms [ 107 , 108 , 109 , 111 , 112 ]. Silaris Influenza A & B Test and BioFire FilmArray Respiratory EZ Panel, however, have not yet been compared in a published research study and the available information about these assays are from the manufacturer.…”

Section: Clia-waived Nucleic Acid Diagnosticsmentioning

confidence: 99%

See 3 more Smart Citations

Nucleic Acid-Based Sensing Techniques for Diagnostics and Surveillance of Influenza

2021

View full text Add to dashboard Cite

Influenza virus poses a threat to global health by causing seasonal outbreaks as well as three pandemics in the 20th century. In humans, disease is primarily caused by influenza A and B viruses, while influenza C virus causes mild disease mostly in children. Influenza D is an emerging virus found in cattle and pigs. To mitigate the morbidity and mortality associated with influenza, rapid and accurate diagnostic tests need to be deployed. However, the high genetic diversity displayed by influenza viruses presents a challenge to the development of a robust diagnostic test. Nucleic acid-based tests are more accurate than rapid antigen tests for influenza and are therefore better candidates to be used in both diagnostic and surveillance applications. Here, we review various nucleic acid-based techniques that have been applied towards the detection of influenza viruses in order to evaluate their utility as both diagnostic and surveillance tools. We discuss both traditional as well as novel methods to detect influenza viruses by covering techniques that require nucleic acid amplification or direct detection of viral RNA as well as comparing advantages and limitations for each method. There has been substantial progress in the development of nucleic acid-based sensing techniques for the detection of influenza virus. However, there is still an urgent need for a rapid and reliable influenza diagnostic test that can be used at point-of-care in order to enhance responsiveness to both seasonal and pandemic influenza outbreaks.

show abstract

Section: Clia-waived Nucleic Acid Diagnosticsmentioning

confidence: 99%

Section: Clia-waived Nucleic Acid Diagnosticsmentioning

confidence: 99%

Section: Clia-waived Nucleic Acid Diagnosticsmentioning

confidence: 99%

Section: Clia-waived Nucleic Acid Diagnosticsmentioning

confidence: 99%

See 2 more Smart Citations

Nucleic Acid-Based Sensing Techniques for Diagnostics and Surveillance of Influenza

2021

View full text Add to dashboard Cite

show abstract

“…It is based on isothermal nucleic acid amplification technology, which uses nicking enzyme amplification reaction (NEAR) technology. As many emerging isothermal amplified POC applications have reached the proof-of-concept stage, ID NOW™ has successfully entered the infectious disease POC market for influenza A & B, Strep A and respiratory syncytial virus (RSV) testing [ 25 – 27 ]. ID NOW™, cobas ® Liat influenza A/B/RSV assays (Roche Molecular Systems, Pleasanton, CA, USA) and GeneXpert ® Xpress Flu/RSV (Cepheid, Sunnyvale, CA, USA) are known as Clinical Laboratory Improvement Amendments (CLIA)-waived (CW) assays that enable non-training personnel to obtain results within 30–50 min and are suitable for POCT [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

Multiplex Molecular Point-of-Care Test for Syndromic Infectious Diseases

et al. 2021

View full text Add to dashboard Cite

Point-of-care (POC) molecular diagnostics for clinical microbiology and virology has primarily focused on the detection of a single pathogen. More recently, it has transitioned into a comprehensive syndromic approach that employs multiplex capabilities, including the simultaneous detection of two or more pathogens. Multiplex POC tests provide higher accuracy to for actionable decisionmaking in critical care, which leads to pathogen-specific treatment and standardized usages of antibiotics that help prevent unnecessary processes. In addition, these tests can be simple enough to operate at the primary care level and in remote settings where there is no laboratory infrastructure. This review focuses on state-of-the-art multiplexed molecular point-of-care tests (POCT) for infectious diseases and efforts to overcome their limitations, especially related to inadequate throughput for the identification of syndromic diseases. We also discuss promising and imperative clinical POC approaches, as well as the possible hurdles of their practical applications as front-line diagnostic tests.

show abstract

Multicenter evaluation of molecular point-of-care testing and digital immunoassays for influenza virus A/B and respiratory syncytial virus in patients with influenza-like illness

Kaku

Kodama

Akamatsu

et al. 2021

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Molecular point-of-care testing for influenza A/B and respiratory syncytial virus: comparison of workflow parameters for the ID Now and cobas Liat systems

Cited by 16 publications

References 18 publications

Nucleic Acid-Based Sensing Techniques for Diagnostics and Surveillance of Influenza

Nucleic Acid-Based Sensing Techniques for Diagnostics and Surveillance of Influenza

Multiplex Molecular Point-of-Care Test for Syndromic Infectious Diseases

Multicenter evaluation of molecular point-of-care testing and digital immunoassays for influenza virus A/B and respiratory syncytial virus in patients with influenza-like illness

Contact Info

Product

Resources

About